vitreomacular adhesion

Showing 1 posts of 1 posts found.

Novartis HQ

Novartis signs experimental eye drug deal

March 19, 2012
Research and Development, Sales and Marketing Novartis, ThromboGenics, vitreomacular adhesion

Novartis will develop an experimental eye drug with ThromboGenics in a pact worth nearly $500 million.  The deal has been …

Latest content